| Target Price | $102.00 |
| Price | $45.42 |
| Potential | 124.57% |
| Number of Estimates | 25 |
| 25 Analysts have issued a price target Rocket Lab 2027 . The average Rocket Lab target price is $102.00. This is 124.57% higher than the current stock price. The highest price target is $133.35 193.59% , the lowest is $58.58 28.97% . | |
| A rating was issued by 30 analysts: 25 Analysts recommend Rocket Lab to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Rocket Lab stock has an average upside potential 2027 of 124.57% . Most analysts recommend the Rocket Lab stock at Purchase. |
27 Analysts have issued a sales forecast Rocket Lab 2026 . The average Rocket Lab sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
22 Analysts have issued an Rocket Lab EBITDA forecast 2026. The average Rocket Lab EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
27 Rocket Lab Analysts have issued a net profit forecast 2026. The average Rocket Lab net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Buy
➜
Buy
|
Unchanged | Nov 11 2026 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Nov 11 2026 |
| BTIG |
Neutral
➜
Neutral
|
Unchanged | Nov 10 2026 |
| Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Nov 10 2026 |
| Keybanc |
Overweight
➜
Overweight
|
Unchanged | Nov 10 2026 |
| Piper Sandler |
Neutral
➜
Neutral
|
Unchanged | Nov 10 2026 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Nov 10 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Needham:
Buy
➜
Buy
|
Nov 11 2026 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Nov 11 2026 |
|
Unchanged
BTIG:
Neutral
➜
Neutral
|
Nov 10 2026 |
|
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Nov 10 2026 |
|
Unchanged
Keybanc:
Overweight
➜
Overweight
|
Nov 10 2026 |
|
Unchanged
Piper Sandler:
Neutral
➜
Neutral
|
Nov 10 2026 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Nov 10 2026 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


